
|Articles|September 13, 2017
Should the Availability of High-Dose Opioids Be Reduced?
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Advertisement
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Removes Black Boxed Warning From Hormone Therapies for Menopause
2
Opinion: Pharmacists Are Critical to Ensure Safe, Ethical Integration of AI in Health Care
3
Major Review Finds No Link Between Maternal Tylenol and Autism Spectrum Disorder, ADHD
4
Advanced Wearable Accelerometer Shows Promise in Detecting Functional Capacity and Outcomes in Heart Failure Patients
5
















































































































































































































